





Distr. GENERAL

CBD/CP/MOP/DEC/9/5 30 November 2018

**ORIGINAL: ENGLISH** 

CONFERENCE OF THE PARTIES TO THE CONVENTION ON BIOLOGICAL DIVERSITY SERVING AS THE MEETING OF THE PARTIES TO THE CARTAGENA PROTOCOL ON BIOSAFETY

Ninth meeting Sharm El-Sheikh, Egypt, 17-29 November 2018 Agenda item 10

## DECISION ADOPTED BY THE PARTIES TO THE CARTAGENA PROTOCOL ON BIOSAFETY

9/5. Monitoring and reporting (Article 33)

The Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on Biosafety,

Recalling decision CP-VIII/14, in which the Executive Secretary was requested to develop a revised format for the fourth national reports with a view to ensuring that complete and accurate information is captured while striving to ensure the applicability of the baseline information, established in decision BS-VI/15,

Welcoming the review by the Subsidiary Body on Implementation at its second meeting of the draft revised format for the fourth national report, as proposed by the Executive Secretary, 1

*Recognizing* the importance of improving the alignment of national reporting under the Convention and its Protocols and of enhancing synergies among the biodiversity-related conventions and the Rio conventions as well as the 2030 Agenda for Sustainable Development<sup>2</sup> and reporting tools for the Sustainable Development Goals, and *noting* the progress made thus far in this respect,

- 1. *Welcomes* the additional third national reports submitted, and *urges* the Parties that have not yet submitted their third national report to do so as soon as possible;<sup>3</sup>
- 2. Adopts the reporting format annexed hereto, and requests Parties to use it for the fourth national report on the implementation of the Cartagena Protocol on Biosafety;
- 3. *Invites* Parties to prepare their reports through a consultative process involving all relevant national stakeholders, including indigenous peoples and local communities, as appropriate;
- 4. *Encourages* Parties to respond to all questions in the reporting format, and stresses the importance of the timely submission of fourth national reports in order to facilitate the fourth assessment and review of the effectiveness of the Cartagena Protocol and the final evaluation of the Strategic Plan for the Cartagena Protocol on Biosafety for the period 2011-2020;<sup>4</sup>

<sup>&</sup>lt;sup>1</sup> See <u>CBD/SBI/2/22</u>, sect. I, recommendation 2/13.

<sup>&</sup>lt;sup>2</sup> General Assembly resolution 70/1 of 25 September 2015.

<sup>&</sup>lt;sup>3</sup> Angola, Azerbaijan, Belize, Cabo Verde, Djibouti, Jordan, Libya, Montenegro, Nauru, Papua New Guinea, Qatar, Saudi Arabia, Serbia, Seychelles, State of Palestine and Syrian Arab Republic.

<sup>&</sup>lt;sup>4</sup> Decision <u>BS-V/16</u>, annex I.

- 5. Requests Parties and invites other Governments to submit to the Secretariat their fourth national report on the implementation of the Cartagena Protocol on Biosafety:
  - (a) In an official language of the United Nations;
- (b) Twelve months prior to the tenth meeting of the Conference of the Parties serving as the meeting of the Parties to the Protocol, which will consider the report;
- (c) Preferably online through the Biosafety Clearing-House, or offline using the appropriate form that will be made available by the Secretariat for this purpose, duly signed by the national focal point for the Cartagena Protocol;
- 6. *Requests* the Executive Secretary to continue making available, in the online reporting tool, the option to view and select the answers provided in the previous national report submitted by the Party concerned;
- 7. Also requests the Executive Secretary to continue to facilitate the offline submission of national reports;
- 8. Recommends to the Conference of the Parties, in adopting guidance to the financial mechanism, that it invite the Global Environment Facility to make available, in a timely manner, financial resources to eligible Parties to facilitate the preparation and submission of their fourth national reports under the Protocol;
- 9. *Accepts* the invitation of the Conference of the Parties to the Convention, contained in decision 14/27, and *decides* to have a synchronized national reporting cycle commencing in 2023.

#### Annex

# UPDATED DRAFT FORMAT FOR THE FOURTH NATIONAL REPORT UNDER THE CARTAGENA PROTOCOL ON BIOSAFETY

#### Origin of the report

1.	Country:	[	Type your text here	]		
Con	Contact person submitting the report					
2.	Name:	]	Type your text here	]		
3.	Title:	]	Type your text here	]		
4.	Organization:	[	Type your text here	]		
5.	Mailing address:	[	Type your text here	1		
6.	Telephone:	[	Type your text here	1		
7.	Fax:	[	Type your text here	1		
8.	E-mail:	[	Type your text here	1		
9.	Organizations/stakeholders who were consulted or participated in the preparation of this report:	[	Type your text here	1		
Sub	mission					
10.	Date of submission:	[	day / month / year	]		
11.	Time period covered by this report:	From [mo	onth / year] to [month / yea	r]		
Signa	Signature of the reporting officer <sup>5</sup>					
12.	If your country is not a Party to the Cartagena Protocol on Biosafety (CPB), is		Yes No			

IMPORTANT: To facilitate the analysis of the information contained in this report, it is recommended that Parties submit the report online through the Biosafety Clearing-House or as an attachment to an e-mail in MS Word format, together with a scanned copy of the signed first page, to the Secretariat at: <a href="mailto:secretariatacechaint">secretariatacechaint</a>.

Please do not send this report via fax or postal mail or in electronic formats other than MS Word.

<sup>&</sup>lt;sup>5</sup> This document is a protected form in MS Word format to enable further processing of the information contained therein by the CBD Secretariat. Only text entries and checkboxes may be changed. Once you finish filling in the form, please save it and print this first page for signature. This form is also available in the BCH for electronic submission at: [LINK TO BE ADDED]

	there any national process in place towards becoming a Party?	
13.	Here you may provide further details:  [ Type your text he	ere ]
	Article 2 – Gener	ral provisions
Arti		propriate legal, administrative and other measures to
14.	Has your country introduced the necessary national measures for the implementation of the Protocol?	<ul> <li>□ National measures are fully in place</li> <li>□ National measures are partially in place</li> <li>□ Only temporary measures have been introduced</li> <li>□ Only draft measures exist</li> <li>□ No measures have yet been taken</li> </ul>
15.	Which specific instruments are in place for the implementation of national biosafety measures?	<ul> <li>□ One or more national biosafety laws</li> <li>□ One or more national biosafety regulations</li> <li>□ One or more sets of biosafety guidelines</li> <li>□ Other laws, regulations or guidelines that indirectly apply to biosafety</li> <li>□ No instruments are in place</li> </ul>
16.	Has your country undertaken initiatives to mainstream biosafety into national biodiversity strategies and action plans, other policies, or legislation?	<ul><li>☐ Yes: [Please specify]</li><li>☐ No</li><li>☐ Other: [Please specify]</li></ul>
17.	Has your country established a mechanism for budget allocations for the operation of its national biosafety measures?	<ul><li>☐ Yes</li><li>☐ Yes, to some extent: [Please specify]</li><li>☐ No</li></ul>
18.	Does your country have permanent staff to administer functions directly related to biosafety?	<ul><li>☐ Yes</li><li>☐ No</li></ul>
19.	If you answered <i>Yes</i> to question 18, how many permanent staff members are in place whose functions are directly related to biosafety?	□       1 to 4         □       5 to 9         □       10 or more         Is this number adequate: □ Yes □ No
20.	Here you may provide further details on the implement [ Type your text here	
	Type your tent ne	J

	Article 5 – Pharmaceuticals				
21.	Does your country regulate the transboundary movement, handling or use of living modified organisms (LMOs) which are pharmaceuticals to humans?		Yes Yes, to some extent: [Please specify] No		
22.	Here you may provide further details on the impleme	entation o	of Article 5 in your country:		
	[ Type your text he	ere	1		
	Article 6 – Transit a	nd conta	ined use		
23.	Does your country regulate the transit of LMOs?		Yes Yes, to some extent: [Please specify] No		
24.	Does your country regulate the contained use of LMOs?		Yes No		
25.	Has your country taken a decision concerning the import of LMOs for contained use?		Yes No		
26.	26. Here you may provide further details on the implementation of Article 6 in your country:  [ Type your text here ]				
	Articles 7 to 10: Advance info intentional introduction of LN				
27.	Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?		Yes Yes, to some extent: [Please specify] No		
28.	When acting as the Party of export, has your country established legal requirements for the accuracy of information contained in the notification provided by the exporter?		Yes Yes, to some extent: [Please specify] No Not applicable (Party currently not exporting LMOs)		
29.	In the current reporting period, has your country received a notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?		Yes No		

30.	If you answered <i>Yes</i> to question 29, did the notification(s) contain complete information (at a minimum the information specified in Annex I to the Cartagena Protocol on Biosafety)?		Yes, always In some cases only No
31.	If you answered <i>Yes</i> to question 29, has your country acknowledged receipt of the notification(s) to the notifier within ninety days of receipt?		Yes, always In some cases only No
32.	If you answered Yes to question 29, has your country	informe	d of its decision(s):
	a. The notifier?		Yes, always In some cases only No
	b. The Biosafety Clearing-House (BCH)?		Yes, always In some cases only No
33.	In the current reporting period, has your country taken a decision in response to the notification(s) regarding intentional transboundary movements of LMOs for intentional introduction into the environment?		Yes No
34.	If you answered <i>Yes</i> to question 33, how many LMOs has your country approved for import for intentional introduction into the environment?		None 1 to 4 5 to 9 10 or more
35.	If you answered <i>under question 34</i> that <i>LMOs were approved</i> , have all these LMOs actually been imported into your country?		Yes, always In some cases only No
36.	If you answered <i>Yes</i> to question 33, what percentage of your country's decisions fall into the following categories?	[ %] [ %] [ %] [ %]	Approval of the import/use of the LMO(s) without conditions  Approval of the import/use of the LMO(s) with conditions  Prohibition of the import/use of the LMO(s)  Request for additional relevant information  Inform the notifier that the period for communicating the decision has been extended

37.	If you answered <i>under question 36</i> that your country has taken a decision to <i>approve the import with conditions</i> or to <i>prohibit the import</i> , were the reasons provided?  Here you may provide further details on the impleme including measures in case of lack of scientific certaintentional introduction to the environment:  [ Type your text he	nty on po	otential adverse effects of LMOs for	
	Article 11 – Procedure for li intended for direct use as food or fee			
39.	Does your country have law(s), regulation(s) or administrative measures for decision-making regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?		Yes No	
40.	Has your country established legal requirements for the accuracy of information to be provided by the applicant regarding the domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?		Yes Yes, to some extent: [Please specify] No	
41.	In the current reporting period, how many decisions has your country taken regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?		None 1 to 4 5 to 9 10 or more	
42.	Does your country have law(s), regulation(s) or administrative measures for decision-making regarding the import of LMOs for direct use as food or feed, or for processing?		Yes No	
43.	In the current reporting period, how many decisions has your country taken regarding the import of LMOs for direct use as food or feed, or for processing?		None 1 to 4 5 to 9 10 or more	
44.	measures in case of lack of scientific certainty on pote to transboundary movement for direct use as food or form	dere you may provide further details on the implementation of Article 11 in your country, including neasures in case of lack of scientific certainty on potential adverse effects of LMOs that may be subject o transboundary movement for direct use as food or feed, or for processing:		
	Type your text he	10	]	

Article 12 – Review of decision				
45.	Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?		Yes Yes, to some extent: [Please specify] No	
46.	In the current reporting period, has your country reviewed and/or changed a decision regarding an intentional transboundary movement of an LMO?		Yes No	
47.	If you answered <i>Yes</i> to question 46, how many decisions were reviewed and/or changed?		1 to 4 5 to 9 10 or more	
48.	If you answered <i>Yes</i> to question 46, were any of the reviews triggered by a request from the Party of export or the notifier?		Yes No	
49.	If you answered <i>Yes</i> to question 48, did your country provide a response within ninety days setting out the reasons for the decision?		Yes, always In some cases only No	
50.	If you answered <i>Yes</i> to question 46, were any of the reviews initiated by your country as the Party of import?		Yes No	
51.	If you answered <i>Yes</i> to question 50, did your country decision and inform:	, within t	hirty days, set out the reasons for the	
	a. The notifier?		Yes, always In some cases only No	
	b. The BCH?		Yes, always In some cases only No	
52.	Here you may provide further details on the implement	entation o	of Article 12 in your country:	
	[ Type your text he	ere	]	
	Article 13 – Simpli	ified pro	cedure	
53.	Has your country established a mechanism for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?		Yes Yes, to some extent: [Please specify] No	

54.	In the current reporting period, has your country applied the simplified procedure?		Yes No	
55.	If you answered <i>Yes</i> to question 54, for how many LMOs has your country applied the simplified procedure?		None 1 to 5 5 or more	
56.	If you answered <i>Yes</i> to question 54, has your country informed the Parties through the BCH of the cases where the simplified procedure was applied?		Yes, always In some cases only No	
57.	Here you may provide further details on the implement	entation o	f Article 13 in your country:	
	[ Type your text he	ere	1	
	Article 14 – Bilateral, regional and multi	lateral aş	greements and arrangements	
58.	How many bilateral, regional or multilateral agreements or arrangements relevant to biosafety has your country established with other Parties/non-Parties?		None 1 to 4 5 to 9 10 or more	
59.	59. If you answered <i>under question 58</i> that <i>agreements or arrangements were established</i> , please provide a brief description of their scope and objective:			
	[ Type your text he	Type your text here ]		
60.	Here you may provide further details on the implement	entation o	f Article 14 in your country:	
	[ Type your text he	ere	]	
	Articles 15 & 16 – Risk assessi	ment and	risk management	
61.	Does the domestic regulatory framework of your country require risk assessments of LMOs to be conducted?		Yes No	
62.	If you answered <i>Yes</i> to question 61, with regard to which LMOs does the requirement apply (select all that apply)?		For imports of LMOs for intentional introduction into the environment  For imports of LMOs intended for direct use as food or feed, or for processing  For decisions regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movements for direct use as food or feed, or for processing  For imports of LMOs for contained use	
l		$\sqcup$	Other: [Please specify]	

63.	Has your country established a mechanism to conduct risk assessments prior to taking decisions regarding LMOs?  If you answered <i>Yes</i> to question 63, does the mechanism include procedures to identify and/or train national experts to conduct risk assessments?		Yes, to some extent: [Please specify] No  Yes No
Сара	acity-building in risk assessment or risk management		
65.	How many people in your country have been trained monitoring of LMOs?	in risk as	ssessment, risk management and
	a. Risk assessment:		None 1 to 9 10 to 49 50 to 99 100 or more
	b. Risk management:		None 1 to 9 10 to 49 50 to 99 100 or more number adequate:  Yes  No
	c. Monitoring:	☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐	None 1 to 9 10 to 49 50 to 99 100 or more number adequate: ☐ Yes ☐ No
66.	Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?		Yes No
67.	If you answered <i>Yes</i> to question 66, is your country using the "Manual on Risk Assessment of LMOs" (developed by the CBD Secretariat) for training in risk assessment?		Yes No

68.	If you answered Yes to question 66, is your country using the "Guidance on Risk Assessment of LMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for training in risk assessment?		Yes No		
69.	Does your country have specific needs for further guidance on specific topics of risk assessment of LMOs?		Yes: [Please specify] No		
70.	Does your country have the capacity to detect, identi specific traits that may have adverse effects on the codiversity, taking into account risks to human health?				
	a. Detect:		Yes No		
	b. Identify:		Yes No		
	c. Assess the risk:		Yes No		
	d. Monitor:		Yes No		
Cond	Conducting risk assessment or risk management				
71.	Has your country adopted or used any guidance docu assessment or risk management, or for evaluating ris				
	a. Risk assessment:		Yes No		
	b. Risk management:		Yes No		
72.	If you answered <i>Yes</i> to question 71, is your country using the "Guidance on Risk Assessment of LMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?		Yes No		
73.	Has your country adopted common approaches or methodologies to risk assessment in coordination with other countries?		Yes No		

74.	Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?	Yes No
75.	In the current reporting period, has your country conducted any kind of risk assessment of LMOs, including for contained use, field trials, commercial purposes, direct use as food, feed, or for processing?	Yes No
76.	If you answered <i>Yes</i> to question 75, how many risk assessments were conducted?	1 to 9 10 to 49 50 to 99 More than 100
		LMOs for contained use (in accordance with Article 3)  LMOs for intentional introduction into the environment for experimental testing or
77.	If you answered <i>Yes</i> to question 75, please indicate the scope of the risk assessments (select all that apply):	field trials  LMOs for intentional introduction into the environment for commercial purposes  LMOs for direct use as food  LMOs for direct use as feed  LMOs for processing  Other: [Please specify]
78.	If you answered <i>Yes</i> to question 75, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?	Yes, always In some cases only No
79.	Has your country established appropriate mechanisms, measures and strategies to regulate and manage risks identified in the risk assessment of LMOs?	Yes No
80.	Has your country taken appropriate measures to prevent unintentional transboundary movements of LMOs, including such measures as requiring a risk assessment to be carried out prior to the first release of a LMO?	Yes No

81.	Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?		Yes Yes, to some extent: [Please specify] No
82.	Has your country established a mechanism for monitoring potential effects of LMOs released into the environment?		Yes, to some extent: [Please specify] No
83.	Does your country have the necessary infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs?		Yes No
84.	Here you may provide further details on the implement		f Articles 15 and 16 in your country:
	Type your text he  Article 17 – Unintentional transboundary		nts <sup>6</sup> and amargancy massures
	Article 17 – Chilitentional transpoundary	liovenie	nts and energency measures
85.	Has your country established measures to notify affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations in case of a release under its jurisdiction that leads, or may lead, to an unintentional transboundary movement?		Yes, to some extent: [Please specify] No
86.	In the current reporting period, how many releases of LMOs occurred under your country's jurisdiction that led, or may have led, to an unintentional transboundary movement?		None 1 to 4 5 to 9 10 or more
87.	If you answered <i>under question 86</i> that a <i>release occurred</i> , has your country notified affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations?		Yes, always In some cases only No
88.	Does your country have the capacity to take appropriate response measures in response to unintentional transboundary movements?		Yes No
89.	In the current reporting period, how many times has your country become aware of an		None

<sup>&</sup>lt;sup>6</sup> In accordance with the operational definition adopted in decision CP-VIII/16, "'Unintentional transboundary movement' is a transboundary movement of a living modified organism that has inadvertently crossed the national borders of a Party where the living modified organism was released, and the requirements of Article 17 of the Protocol apply to such transboundary movements only if the living modified organism involved is likely to have significant adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, in the affected or potentially affected States."

	unintentional transboundary movement into its territory?		1 to 4 5 to 9
			10 or more
90.	Here you may provide further details on the implementation	entation	of Article 17 in your country:
	[ Type your text h	nere	1
	Article 18 – Handling, transpor	t, packa	ging and identification
91.	Has your country taken measures to require that <i>LMOs that are subject to transboundary movement</i> are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?		Yes Yes, to some extent: [Please specify] No
92.	Has your country taken measures to require that documentation accompanying LMOs-FFP, in cases where the identity of the LMOs is not known, clearly identifies that they may contain LMOs and are not intended for intentional introduction into the environment, as well as a contact point for further information?		Yes Yes, to some extent: [Please specify] No
93.	Has your country taken measures to require that documentation accompanying LMOs-FFP, in cases where the identity of the LMOs is known, clearly identifies that they contain LMOs and are not intended for intentional introduction into the environment, as well as a contact point for further information?		Yes Yes, to some extent: [Please specify] No
94.	If you answered <i>Yes</i> to question(s) 91, 92 and/or 93, what type of documentation accompanying LMOs does your country require?		Documentation specific for LMOs  As part of other documentation (not specific for LMOs)  Other: [Please specify]
95.	Has your country taken measures to require that documentation accompanying <i>LMOs</i> that are destined for contained use clearly identifies them as <i>LMOs</i> and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?		Yes Yes, to some extent: [Please specify] No
96.	If you answered <i>Yes</i> to question 95, what type of documentation does your country		Documentation specific for LMOs

	require for the identification of LMOs that are destined for contained use?		As part of other documentation (not specific for LMOs)
			Other: [Please specify]
97.	Has your country taken measures to require that documentation accompanying <i>LMOs</i> that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?		Yes Yes, to some extent: [Please specify] No
98.	If you answered <i>Yes</i> to question 97, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment?		Documentation specific for LMOs  As part of other documentation (not specific for LMOs)  Other: [Please specify]
99.	Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms?		Yes No
100.	Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?		Yes, to some extent: [Please specify] No
101.	How many customs officers in your country have received training in the identification of LMOs?	☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐	None 1 to 9 10 to 49 50 to 99 100 or more  number adequate: ☐ Yes ☐ No
102.	Has your country established procedures for the sampling and detection of LMOs?		Yes, to some extent: [Please specify] No
103.	How many laboratory personnel in your country have received training in detection of LMOs?		None 1 to 9 10 to 49

☐ 100 or more  Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  No  No  No  105. How many laboratories in your country are	Is this number adequate: ☐ Yes ☐ No  Does your country have reliable access to laboratory facilities for the detection of LMOs?  Is this number adequate: ☐ Yes ☐ No		50 to 99	
104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  No  None  105. How many laboratories in your country are	. Does your country have reliable access to laboratory facilities for the detection of LMOs?  Yes  No			100 or more
laboratory facilities for the detection of LMOs?  No  None  105 How many laboratories in your country are	laboratory facilities for the detection of LMOs? No	Is this number adequate: \( \sum \) Yes \( \sum \) No	☐ 100 or more	Is this number adequate:   Yes No
laboratory facilities for the detection of LMOs?  No  None  105 How many laboratories in your country are	laboratory facilities for the detection of LMOs? No			104 Does your country have reliable access to
None  105 How many laboratories in your country are	Livios:	104 Does your country have reliable access to	Is this number adequate: \( \sum \) Yes \( \sum \) No	laboratory facilities for the detection of
105 How many laboratories in your country are		laboratory facilities for the detection of	Is this number adequate: Yes No  104. Does your country have reliable access to laboratory facilities for the detection of	
105 How many laboratories in your country are	None	laboratory facilities for the detection of	Is this number adequate: Yes No  104. Does your country have reliable access to laboratory facilities for the detection of	LMOs?
105. How many laboratories in your country are	<del>-</del>	laboratory facilities for the detection of LMOs?	Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  Yes ☐ No	
		laboratory facilities for the detection of LMOs?  No  No  Noe  1 to 4	Is this number adequate:    Yes	□ None □ 1 to 4
10 to 49		laboratory facilities for the detection of LMOs?  No  No  No  105. How many laboratories in your country are	Is this number adequate:     Yes	None  105. How many laboratories in your country are  None  1 to 4
50 or more	certified for LMO detection?	laboratory facilities for the detection of LMOs?  No  No  No  No  105. How many laboratories in your country are certified for LMO detection?  Sto 9	Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  □ No □ None □ 1 to 4 □ 5 to 9	None    1 to 4     5 to 9     5 to 9
☐ None	certified for LMO detection?	laboratory facilities for the detection of LMOs?  No  No  No  No  No  105. How many laboratories in your country are certified for LMO detection?  No  1 to 4  1 to 9  1 to 49	Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  No  No  No  No  105. How many laboratories in your country are certified for LMO detection?  106. How many laboratories in your country are certified for LMO detection?  107. No  None  108. To 4  109. To 49	None    1 to 4     5 to 9     10 to 49
106. If you answered <i>under question 105</i> that	certified for LMO detection?  10 to 49  50 or more	laboratory facilities for the detection of LMOs?  No  No  No  No  No  No  105. How many laboratories in your country are certified for LMO detection?  105. How many laboratories in your country are certified for LMO detection?  105. How many laboratories in your country are country	Is this number adequate:   Yes   No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?   Yes   No    No   None   1 to 4   5 to 9   10 to 49   50 or more	None    1 to 4     5 to 9     10 to 49     50 or more
	certified for LMO detection?  \[ \begin{array}{ c c c c c c c c c c c c c c c c c c c	laboratory facilities for the detection of LMOs?  No  None  1 to 4  1 to 4  5 to 9  1 to 49  5 to or more  None  106. If you answered under question 105 that  No  None	Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  105. How many laboratories in your country are certified for LMO detection?  106. If you answered under question 105 that  107. Yes ☐ Yes ☐ No ☐ None ☐ 1 to 4 ☐ 5 to 9 ☐ 10 to 49 ☐ 50 or more ☐ None ☐ None ☐ None ☐ None ☐ None ☐ I to 4	None    1 to 4     5 to 9     10 to 49     50 or more  106. If you answered under question 105 that
in the detection of LMOs? 10 to 49	certified for LMO detection?  10 to 49  50 or more  None  If you answered under question 105 that certified laboratories exist in your country,  5 to 9	laboratory facilities for the detection of LMOs?  No  None  1 to 4  1 to 4  5 to 9  10 to 49  50 or more  106. If you answered under question 105 that certified laboratories exist in your country,  106. If you answered under question 105 that certified laboratories exist in your country,  107. None  108. None  109. None  100. If you answered under question 105 that certified laboratories exist in your country,  109. None  100. Sto 9  100. Sto 9  100. Sto 9  100. Sto 9	Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  No  None ☐ 1 to 4 ☐ 10 to 49 ☐ 50 or more  106. If you answered under question 105 that certified laboratories exist in your country,  This number adequate: ☐ Yes ☐ No ☐ None ☐ 1 to 4 ☐ 1 to 4 ☐ 50 or more ☐ None ☐ 1 to 4 ☐ 50 or more ☐ None ☐ 1 to 4 ☐ 5 to 9 ☐ 50 or more	None    1 to 4     5 to 9     10 to 49     50 or more    106. If you answered under question 105 that certified laboratories exist in your country,   5 to 9     10 to 49     50 or more   10 to 49     50 or more   10 to 4     10 to 4
50 or more	certified for LMO detection?  \begin{array}{ c c c c c c c c c c c c c c c c c c c	laboratory facilities for the detection of LMOs?  No  None  105. How many laboratories in your country are certified for LMO detection?  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating  No  None  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating	Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  105. How many laboratories in your country are certified for LMO detection?  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating	None    1 to 4     5 to 9     10 to 49     50 or more    106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating   5 to 9     10 to 49     50 or more   10 to 4     1 to 4     5 to 9     5 to 9     5 to 9     5 to 9     6 to 9     7 to 4     7 to 4     8 to 9     9 to 9     1 to 4     1 to 9     1
30 or more	certified for LMO detection?  \begin{array}{ c c c c c c c c c c c c c c c c c c c	laboratory facilities for the detection of LMOs?  No  None  1 to 4  105. How many laboratories in your country are certified for LMO detection?  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating in the detection of LMOs?  No  None  1 to 4	Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  105. How many laboratories in your country are certified for LMO detection?  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating in the detection of LMOs?  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating in the detection of LMOs?	None    1 to 4     1 to 4     5 to 9     10 to 49     50 or more    106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating in the detection of LMOs?
107. Here you may provide further details on the implementation of Article 18 in your country:	certified for LMO detection?  \[ \begin{array}{ c c c c c c c c c c c c c c c c c c c	laboratory facilities for the detection of LMOs?  None    None     1 to 4     5 to 9     10 to 49     50 or more    None     1 to 4     10 to 49     5 to 9     10 to 49     50 or more	Is this number adequate:   Yes   No	None   1 to 4   5 to 9   10 to 49   50 or more   1 to 4   1 to 4
	certified for LMO detection?    10 to 49   50 or more	laboratory facilities for the detection of LMOs?  None  105. How many laboratories in your country are certified for LMO detection?  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating in the detection of LMOs?  None  None  None  1 to 4  5 to 9  None  1 to 4  5 to 9  10 to 49	Is this number adequate:   Yes   No	None   1 to 4   5 to 9   10 to 49   50 or more   1 to 4   1 to 4
107. Here you may provide further details on the implementation of Article 18 in your country:	certified for LMO detection?    10 to 49   50 or more	laboratory facilities for the detection of LMOs?    No	Is this number adequate: ☐ Yes ☐ No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  105. How many laboratories in your country are certified for LMO detection?  106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating in the detection of LMOs?  107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here ]	None   1 to 4   5 to 9   10 to 49   50 or more   1 to 4   1 to 4
107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here ]  Article 19 – Competent national authorities and national focal points	certified for LMO detection?	laboratory facilities for the detection of LMOs?    None   1 to 4   5 to 9   10 to 49   50 or more	Is this number adequate:   Yes   No	None     1 to 4     10 to 49     50 or more     10 to 49     5 to 9     10 to 49     50 or more     107. Here you may provide further details on the implementation of Article 18 in your country:   1 Type your text here   1   1 to 4     1 to
107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here ]  Article 19 – Competent national authorities and national focal points  Yes	certified for LMO detection?	laboratory facilities for the detection of LMOs?    None	Is this number adequate:   Yes   No	None     1 to 4   1 to 4   10 to 49   50 or more   10 to 49   10
107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here ]  Article 19 – Competent national authorities and national focal points    Yes   No   No     than one competent national authority, has	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?    None	Is this number adequate:   Yes   No	None   1 to 4   5 to 9   10 to 49   50 or more   1 to 4   1 to 4
107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here ]  Article 19 – Competent national authorities and national focal points    Yes   No   No   No   No applicable (no competent national authority)	certified for LMO detection?	laboratory facilities for the detection of LMOs?    None     1 to 4     1 to	Is this number adequate:   Yes   No	None     1 to 4     5 to 9     10 to 49     5 to 9     10 to 49     50 or more   107. Here you may provide further details on the implementation of Article 18 in your country:    Type your text here   1
107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here ]  Article 19 – Competent national authorities and national focal points    Yes	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?    None     None     1 to 4     5 to 9     10 to 49     50 or more     1 to 4     1	Is this number adequate:   Yes   No	None   1 to 4   5 to 9   10 to 49   50 or more   100.   If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating in the detection of LMOs?   None   10 to 49   50 or more   10 to 49
107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here ]  Article 19 – Competent national authorities and national focal points    Yes	certified for LMO detection?	laboratory facilities for the detection of LMOs?	Is this number adequate:   Yes   No	None   1 to 4   1 to 4   10 to 49   10 to
107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here	certified for LMO detection?    10 to 49	105. How many laboratories in your country are certified for LMO detection?	Is this number adequate:   Yes   No	None   1 to 4   5 to 9   10 to 49   50 or more   1 to 4   5 to 9   10 to 49   50 or more   106. If you answered under question 105 that certified laboratories exist in your country, how many of them are currently operating in the detection of LMOs?   10 to 49   50 or more   107. Here you may provide further details on the implementation of Article 18 in your country:    Type your text here
107. Here you may provide further details on the implementation of Article 18 in your country:  [	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?	Is this number adequate:   Yes   No	None     1 to 4     5 to 9     10 to 49     50 or more     1 to 4     5 to 9     10 to 49     50 or more     10 to 49     5 to 9     10 to 49     50 or more     10 to 49     50 or more   10 to 49     10
107. Here you may provide further details on the implementation of Article 18 in your country:  [	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?	Is this number adequate:   Yes   No	None     1 to 4     5 to 9     10 to 49     50 or more     1 to 4     1 to 4   1 to 4   1 to 4   1 to 4   1 to 4   1 to 4   1 to 4
107. Here you may provide further details on the implementation of Article 18 in your country:  [	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?	Is this number adequate:   Yes   No	None   1 to 4   1 t
107. Here you may provide further details on the implementation of Article 18 in your country:  [ Type your text here ]  Article 19 – Competent national authorities and national focal points    Yes   No   No   Not applicable (no competent national authority was designated)   Not applicable (noly one competent national authority was designated)   Not applicable (only one competent national authority was designated)   Not applicable (only one competent national authority was designated)   Not applicable (only one competent national authority was designated)   Not applicable (only one competent national authority was designated)   Not applicable (only one competent national authority was designated)   Yes   No   Not applicable (only one competent national authority was designated)   No   Not applicable (only one competent national authority was designated)   No   No   Not applicable (only one competent national authority was designated)   No   No   No   No   No   No   No   N	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?	Is this number adequate:   Yes   No	None   1 to 4   1 t
107. Here you may provide further details on the implementation of Article 18 in your country:  [	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?	Is this number adequate:   Yes   No	None
107. Here you may provide further details on the implementation of Article 18 in your country:  [	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?	Is this number adequate:   Yes   No	None
107. Here you may provide further details on the implementation of Article 18 in your country:  [	certified for LMO detection?    10 to 49	laboratory facilities for the detection of LMOs?	104. Does your country have reliable access to laboratory facilities for the detection of LMOs?	None
5. How many laboratories in your country are	l		Is this number adequate:  \[ Yes \] No  4. Does your country have reliable access to \[ Yes \]	
LMOs?  No  None  105 How many laboratories in your country are	LMOs? No			
104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  No  None  105. How many laboratories in your country are	. Does your country have reliable access to laboratory facilities for the detection of LMOs?  Yes  No	In this number adoption     Vos     Mo	100 or more	
Is this number adequate:  \[ Yes \] No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  No  None  105. How many laboratories in your country are	Is this number adequate: ☐ Yes ☐ No  Does your country have reliable access to laboratory facilities for the detection of LMOs?  Is this number adequate: ☐ Yes ☐ No			100 or more
Is this number adequate:  \[ Yes \] No  104. Does your country have reliable access to laboratory facilities for the detection of LMOs?  No  None  105. How many laboratories in your country are	Is this number adequate: ☐ Yes ☐ No  Does your country have reliable access to laboratory facilities for the detection of LMOs?  Is this number adequate: ☐ Yes ☐ No		☐ 50 to 99	

	Article 20 – Information sharing and	the Biosa	fety Clearing-House (BCH)
112.	Please provide an overview of the status of the mand BCH by specifying for each category of information submitted to the BCH.		
a.	Existing legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))		Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
b.	Legislation, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)		Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
c.	Bilateral, multilateral and regional agreements and arrangements (Article 14, paragraph 2, and Article 20, paragraph 3 (b))		Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
d.	Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))		Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
e.	Decisions by a Party regarding transit of LMOs (Article 6, paragraph 1)		Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
f.	Decisions by a Party regarding import of LMOs for contained use (Article 6, paragraph 2)		Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
g.	Notifications regarding the release under your country's jurisdiction that leads, or		Information available and in the BCH

	may lead, to an unintentional transboundary movement of a LMO that is likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)	Information available but not in the BCH Information available but only partially available in the BCH Information not available
h.	Information concerning cases of illegal transboundary movements of LMOs (Article 25, paragraph 3)	Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
i.	Decisions regarding the importation of LMOs for intentional introduction into the environment (Article 10, paragraph 3)	Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
j.	Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)	Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
k.	Decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)	Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
1.	Decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with Annex III to the Protocol (Article 11, paragraph 6)	Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available
m.	Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)	Information available and in the BCH Information available but not in the BCH Information available but only partially available in the BCH Information not available

			Information available and in the BCH
n.	Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)		Information available but not in the BCH
			Information available but only partially available in the BCH
			Information not available
0.	Cases where intentional transboundary		Information available and in the BCH
	movement may take place at the same time		Information available but not in the BCH
	as the movement is notified to the Party of import (Article 13, paragraph 1 (a))		Information available but only partially available in the BCH
			Information not available
		_	Information available and in the BCH
			Information available but not in the BCH
p.	LMOs granted exemption status by each Party (Article 13, paragraph 1 (b))		Information available but only partially
			available in the BCH
			Information not available
q.	Summaries of risk assessments or		Information available and in the BCH
4.	environmental reviews of LMOs generated		Information available but not in the BCH
	by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))		Information available but only partially available in the BCH
	(Article 20, paragraph 5 (c))		Information not available
113.	Please provide a brief explanation if you answered to or only partially available in the BCH to any item us		
	[ Type your text h	ere	1
114	Has your country established a mechanism		Yes
11	for strengthening the capacity of the BCH		Yes, to some extent: [Please specify]
	national focal point to perform its administrative functions?		No
115	***		
115.	Has your country established a mechanism for the coordination among the BCH national		Yes
	focal point, the Cartagena Protocol national focal point, and the competent national authority(ies) for making information available to the BCH?		Yes, to some extent: [Please specify]
			No
			Yes, always
116.	Does your country use the information available in the BCH in its decision-making processes on LMOs?		Yes, in some cases
			No
			Not applicable (no decisions were taken)

117.	Has your country experienced difficulties		Yes: [Please specify]
	accessing or using the BCH?		No
			None
118.	In the current reporting period, how many		1 to 4
	biosafety-related events (e.g. seminars, workshops, press conferences, educational		5 to 9
	events) has your country organized?		10 to 24
			25 or more
			None
110	In the gurrant reporting period, how many		1 to 9
119.	In the current reporting period, how many biosafety-related publications has your		10 to 49
	country published?		50 to 99
			100 or more
120.	Here you may provide further details on the implementation	entation o	of Article 20 in your country:
1201	[ Type your text he		]
	Article 21 – Confide	antial inf	ormation
	Article 21 – Connuc		ormation
121.	Has your country established procedures to		Yes
	protect confidential information received		Yes, to some extent: [Please specify]
	under the Protocol?		No
122	Does your country allow the notifier to		Yes, always
122.	identify information that is to be treated as		In some cases only
	confidential?		No
123.	Here you may provide further details on the implementation	entation c	of Article 21 in your country:
	[ Type your text he		]
	Article 22 – Cap	ooity bu	ilding
	Article 22 – Cap	acity-bui	numg
124.	Does your country have predictable and reliable		Yes
	funding for building capacity for the effective		Yes, to some extent: [Please specify]
	implementation of the Protocol?		No
125.	Has your country received external support		Yes
	or benefited from collaborative activities with other Parties in the development and/or		Yes, to some extent: [Please specify]
	strengthening of human resources and		No
	institutional capacities in biosafety?		110
126.	If you answered <i>Yes</i> to question 125, how		Bilateral channels
	were these resources made available?		Regional channels

		Multilateral channels
127.	Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?	Yes Yes, to some extent: [Please specify] No
128.	If you answered <i>Yes</i> to question 127, how were these resources made available?	Bilateral channels Regional channels Multilateral channels
129.	In the reporting period, has your country initiated a process to access funds from the Global Environment Facility (GEF) for building capacity in biosafety?	Yes: [Please specify] No
130.	If you answered <i>Yes</i> to question 129, how would you characterize the process?	Very easy Easy Average Difficult Very difficult
131.	In the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?	Yes Yes, to some extent: [Please specify] No
132.	If you answered <i>Yes</i> to question 131, in which of the following areas were these activities undertaken (select all that apply)?	Institutional capacity and human resources Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety) Risk assessment and other scientific and technical expertise Risk management Public awareness, participation and education in biosafety Information exchange and data management, including participation in the Biosafety Clearing-House Scientific, technical and institutional collaboration at subregional, regional and international levels Technology transfer Identification of LMOs, including their detection Socioeconomic considerations Implementation of the documentation requirements under Article 18.2 of the Protocol Handling of confidential information

		Measures to address unintentional and/or illegal transboundary movements of LMOs Scientific biosafety research relating to LMOs Taking into account risks to human health Liability and redress  Other: [Please specify]
133.	In the current reporting period, has your country carried out a capacity-building needs assessment?	Yes No
134.	Does your country still have capacity-building needs?	Yes No
135.	If you answered <i>Yes</i> to question 134, which of the following areas still need capacity-building (select all that apply)?	Institutional capacity and human resources Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety) Risk assessment and other scientific and technical expertise Risk management Public awareness, participation and education in biosafety Information exchange and data management, including participation in the Biosafety Clearing-House Scientific, technical and institutional collaboration at subregional, regional and international levels Technology transfer Sampling, detection and identification of LMOs Socioeconomic considerations Implementation of the documentation requirements for handling, transport, packaging and identification Handling of confidential information Measures to address unintentional and/or illegal transboundary movements of LMOs Scientific biosafety research relating to LMOs Taking into account risks to human health Liability and redress Other: [Please specify]
136.	Has your country developed a capacity-building strategy or action plan?	Yes No
137.	Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?	Yes No

138.	Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:			
	[ Type your text	here ]		
	Article 23 – Public awar	reness and participation		
139.	Is biosafety public awareness, education and/or participation addressed in legislation or policy in your country?	<ul><li>☐ Yes</li><li>☐ Yes, to some extent: [Please specify]</li><li>☐ No</li></ul>		
140.	In the current reporting period, has your country cooperated with other States and international bodies in relation to public awareness, education and participation?	Yes: [Please specify] No		
141.	Has your country established a mechanism to ensure public access to information on LMOs?	<ul><li>☐ Yes</li><li>☐ Yes, to some extent: [Please specify]</li><li>☐ No</li></ul>		
142.	Does your country have in place a national communication strategy on biosafety?	Yes: [Please specify] No		
143.	Does your country have any awareness and outreach programmes on biosafety?	Yes: [Please specify] No		
144.	Does your country currently have a national biosafety website?	☐ Yes ☐ No		
145.	How many academic institutions in your country are offering biosafety education and training courses and programmes?	□         None           □         1 to 4           □         5 to 9           □         10 or more   Is this number adequate: □ Yes □ No		
146.	How many educational materials and/or online modules on biosafety are available and accessible to the public in your country?	None		

147.	Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?	Yes, to some extent: [Please specify] No
148.	Has your country informed the public about existing modalities for public participation in the decision-making process regarding LMOs?	Yes Yes, to some extent: [Please specify] No
149.	If you answered <i>Yes</i> to question 148, please indicate the modalities used to inform the public:	National websites Newspapers Forums Mailing lists Public hearings Social media Other: [Please specify]
150.	In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs?	None (decisions taken without consultation)  1 to 4  5 or more  Not applicable (no decisions were taken)
151.	Has your country informed the public about the means to access the Biosafety Clearing-House?	Yes No
152.	Here you may provide further details on the implen  [ Type your text ]	of Article 23 in your country:
	Article 24 –	
153.	Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?	Yes No
154.	In the current reporting period, has your country imported LMOs from a non-Party?	Yes No
155.	In the current reporting period, has your country exported LMOs to a non-Party?	Yes No
156.	If you answered <i>Yes</i> to question 154 and/or 155, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?	Yes, always In some cases only No

157.	57. Here you may provide further details on the implementation of Article 24 in your country:  [ Type your text here ]				
	[ Type your text]	———	1		
	Article 25 – Illegal transboundary movements <sup>7</sup>				
158.	Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement the Cartagena Protocol?		Yes Yes, to some extent: [Please specify] No		
159.	In the current reporting period, how many cases of illegal transboundary movements of LMOs has your country become aware of?		None 1 to 4 5 to 9 10 or more		
160.	If you indicated under question 159 that your country became aware of cases of illegal transboundary movements, has the origin of the LMO(s) been established?		Yes Yes, some cases No		
161.	Here you may provide further details on the implementation	nentation	of Article 25 in your country:		
	[ Type your text ]	here	1		
	Article 26 – Socio-eco	nomic co	nsiderations		
162.	Does your country have any specific approaches or requirements that facilitate how socioeconomic considerations should be taken into account in LMO decision-making?		Yes No		
163.	In the current reporting period, have socioeconomic considerations arising from the impact of LMOs been taken into account in decision-making?		Yes, always In some cases only No Not applicable (no decisions were taken)		
164.	How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socioeconomic considerations?	☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐	None 1 to 4 5 to 9 10 to 49 50 or more  number adequate:  Yes No		

<sup>&</sup>lt;sup>7</sup> In accordance with the operational definition adopted in decision CP VIII/16, "'Illegal transboundary movement' is a transboundary movement of living modified organisms carried out in contravention of the domestic measures to implement the Protocol that have been adopted by the Party concerned".

165.	Has your country cooperated with other Parties on research and information exchange on any socioeconomic impacts of LMOs?		Yes No
166.	Here you may provide further details on the implen	nentation	of Article 26 in your country:
	[ Type your text l	here	]
	Article 28 – Financial	l mechan	ism and resources
167.	In the current reporting period, how much funding (in the equivalent of US dollars) has your country mobilized to support implementation of the Cartagena Protocol beyond the regular national budgetary allocation?		Nothing 1 to 4,999 USD 5,000 to 49,999 USD 50,000 to 99,999 USD 100,000 to 499,000 USD 500,000 USD or more
	Article 33 – Monito cle 33 requires Parties to monitor <u>the implementation</u> report to the Conference of the Parties serving as the measures taken to imp	n of its ob meeting	oligations under the Cartagena Protocol and to of the Parties to the Cartagena Protocol on
168.	Does your country have in place a system to monitor and enforce the implementation of the Cartagena Protocol?		Yes No
Parti	<b>Nagoya-Kuala Lumpur Supplementa</b> es to the Cartagena Protocol that are not yet Party to to the quest	o the Sup	plementary Protocol are also invited to respond
169.	Is your country a Party to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?		Yes No
170.	If you answered <i>No</i> to question 169, is there any national process in place towards becoming a Party to the Supplementary Protocol?		Yes No
171.	Has your country introduced the necessary measures for the implementation of the Supplementary Protocol?		National measures are fully in place  National measures are partially in place  Only temporary measures have been introduced  Only draft measures exist  No measures have yet been taken

172.	Which instruments are in place for the implementation of the Supplementary Protocol?	One or more national laws: [Please specify]  One or more national regulations: [Please specify]  One or more sets of guidelines: [Please specify]  No instruments are in place		
173.	Does your country have administrative or legal instruments that require response measures to be taken:			
a.	In case of damage resulting from LMOs?	Yes No		
b.	In case there is sufficient likelihood that damage will result if response measures are not taken?	Yes No		
174.	If you answered <i>Yes</i> to question 173a, do these instruments impose requirements on an operator (select all that apply)?	Yes, the operator must inform the competent authority of the damage Yes, the operator must evaluate the damage Yes, the operator must take response measures Yes, other requirements: [Please specify] No		
175.	If you answered <i>Yes</i> to question 173a, do these instruments require the operator to take response measures to avoid damage?	Yes No		
176.	If you answered <i>Yes</i> to question 173a or 173b, do these instruments provide for a definition of "operator"?	Yes No		
177.	If you answered <i>Yes</i> to question 176, which of the following could be an 'operator' (select all that apply)?	Permit holder Person who placed the LMO on the market Developer Producer Notifier Exporter Importer Carrier Supplier Other: [Please specify]		

178.	Has a competent authority been identified for carrying out the functions set out in the Supplementary Protocol?		Yes: [Please specify] No			
179.	If you answered <i>Yes</i> to question 178, what measures may the competent authority take (select all that apply)?		Identify the operator that caused the damage Evaluate the damage Determine response measures to be taken by operator Implement response measures Recover costs and expenses of the evaluation of the damage and the implementation of any response measures from the operator Other: [Please specify]			
180.	Does your country have measures in place to provide for financial security for damage resulting from LMOs?		Yes No			
181.	If you answered <i>Yes</i> to question 180, what type of financial security measures are in place (select all that apply)?		Requirement to provide evidence for secure source of funding  Mandatory insurance  Government schemes, including funds  Other: [Please specify]			
182.	Does your country have rules and procedures on civil liability that address damage resulting from LMOs, or has such damage been recognized in court rulings (select all that apply)?		Yes, in a civil liability instrument Yes, in court rulings Yes, in other instruments: [Please specify] No			
183.	Have there been any occurrences of damage resulting from LMOs in your country?		Yes: [Please specify] No			
184.	If you answered <i>Yes</i> to question 183, have response measures been taken?		Yes: [Please specify] No			
185.	Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress:      Type your text here					
	Other information					
186.	6. Please use this field to provide any other information on issues related to national implementation of the Cartagena Protocol and the Supplementary Protocol, including any obstacles or impediments encountered.					
	[ Type your text here ]					

Comments on reporting format						
187.	7. Please use this field to provide any other information on difficulties that you have encountered in filling in this report.					
	[	Type your text here	]			

\_\_\_\_